Frits van Rhee Selected Research

Castleman Disease (Castleman's Disease)

1/2022	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
1/2022	Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
10/2021	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
1/2021	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
1/2021	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
3/2020	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
1/2020	Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
1/2019	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
1/2019	Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
1/2018	Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frits van Rhee Research Topics

Disease

64	Multiple Myeloma 10/2022 - 01/2003
22	Neoplasms (Cancer) 01/2022 - 05/2005
19	Castleman Disease (Castleman's Disease) 01/2022 - 07/2010
11	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 04/2006
7	Edema (Dropsy) 01/2022 - 04/2016
7	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2013
7	Inflammation (Inflammations) 01/2022 - 01/2019
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2022 - 08/2010
7	Disease Progression 02/2021 - 03/2006
6	Fever (Fevers) 01/2022 - 07/2013
5	Multi-centric Castleman's Disease 10/2021 - 05/2014
4	Anemia 01/2022 - 07/2013
4	Cytokine Release Syndrome 12/2020 - 05/2014
4	Bone Diseases (Bone Disease) 09/2014 - 09/2009
3	Lymphadenopathy 01/2022 - 04/2016
3	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 01/2019
3	Smoldering Multiple Myeloma 02/2021 - 10/2008
3	Fatigue 03/2020 - 07/2013
2	Hypoalbuminemia 01/2022 - 03/2017
2	Genetic Translocation (Chromosomal Translocation) 01/2022 - 07/2014
2	Thrombocytosis (Thrombocythemia) 01/2022 - 03/2017
2	Fibrosis (Cirrhosis) 10/2021 - 01/2018
2	Neutropenia 03/2020 - 07/2013
2	Cytopenia 01/2019 - 03/2017
2	Hematologic Neoplasms (Hematological Malignancy) 11/2018 - 02/2016
2	Leukopenia 10/2015 - 07/2013
2	Hypercholesterolemia 10/2015 - 07/2013
2	Hypertriglyceridemia 10/2015 - 07/2013
2	Leukemia 06/2013 - 08/2012
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2013 - 01/2008
2	Testicular Neoplasms (Testicular Cancer) 05/2011 - 11/2007
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Residual Neoplasm 01/2022
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022
1	Communicable Diseases (Infectious Diseases) 10/2021
1	Renal Insufficiency (Renal Failure) 10/2021
1	Ehrlichiosis 08/2021
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 08/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Nausea 03/2020
1	Hypertension (High Blood Pressure) 03/2020
1	Urinary Retention 03/2020
1	Vomiting 03/2020
1	Carcinogenesis 01/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2019
1	POEMS Syndrome (Syndrome, POEMS) 01/2018
1	Proteinuria 03/2017

Drug/Important Bio-Agent (IBA)

15	Interleukin-6 (Interleukin 6)IBA 01/2022 - 08/2010
13	Monoclonal AntibodiesIBA 01/2022 - 09/2009
12	siltuximabIBA 01/2022 - 08/2010
11	Thalidomide (Thalomid)FDA Link 06/2013 - 07/2003
9	Bortezomib (Velcade)FDA Link 06/2017 - 07/2007
7	CytokinesIBA 01/2022 - 05/2014
6	C-Reactive ProteinIBA 01/2022 - 10/2006
6	Melphalan (Alkeran)FDA LinkGeneric 02/2018 - 03/2006
5	Reticulin (Reticular Fiber)IBA 01/2022 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2007
4	daratumumabIBA 08/2021 - 01/2018
4	elotuzumabIBA 06/2014 - 05/2008
4	AntigensIBA 05/2011 - 05/2005
3	Lenalidomide (CC 5013)FDA Link 07/2021 - 08/2012
3	Messenger RNA (mRNA)IBA 04/2010 - 09/2006
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2009 - 10/2006
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 06/2013
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2018
2	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2022
2	Dexamethasone (Maxidex)FDA LinkGeneric 07/2021 - 08/2010
2	Biological ProductsIBA 01/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 01/2020 - 11/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2016 - 01/2016
2	Proteasome InhibitorsIBA 01/2016 - 02/2008
2	InterleukinsIBA 10/2015 - 08/2014
2	Biomarkers (Surrogate Marker)IBA 10/2015 - 02/2007
2	Pharmaceutical PreparationsIBA 07/2013 - 10/2008
2	VaccinesIBA 09/2010 - 11/2005
1	ChromatinIBA 10/2022
1	SteroidsIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	tisagenlecleucelIBA 01/2022
1	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2021
1	ixazomibIBA 07/2021
1	Cell-Free Nucleic AcidsIBA 02/2021
1	Cytotoxins (Cytolysins)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	ParaffinIBA 01/2019
1	TNF Receptor-Associated Factor 3IBA 02/2018
1	ChemokinesIBA 01/2018

Therapy/Procedure

42	Therapeutics 01/2022 - 07/2003
8	Drug Therapy (Chemotherapy) 03/2022 - 07/2003
7	Stem Cell Transplantation 03/2022 - 09/2006
7	Immunotherapy 04/2017 - 05/2005
5	Transplantation 01/2022 - 04/2006
4	Autologous Transplantation 03/2010 - 08/2007
2	Hematopoietic Stem Cell Transplantation 02/2016 - 03/2006
2	Homologous Transplantation 05/2006 - 01/2003
1	Aftercare (After-Treatment) 01/2022
1	Maintenance Chemotherapy 08/2021
1	Precision Medicine 01/2019